Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, Michael Anderson, Melina Diaz, Kairav Shah, Vishnu V. Chundi, David W. Hines, Brian P. Harting, Kamo Sidwha, Brian Yu, Paul Brune, Anjum Owaisi, David Beezhold, Joseph Kent, Dana Vais, Alice Han, Neethi Gowda, Nishi Sahgal, Jan Silverman, Jonathan Stake, Jenie Nepomuceno, Renuka Heddurshetti
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/8f2e979c953546579043c6871302879b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

Ejemplares similares